Top

Published in:

01-04-2010 | Review Article

Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma

Authors: June-Key Chung, Hye Won Youn, Joo Hyun Kang, Ho Young Lee, Keon Wook Kang

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2010

Abstract

Since the specific accumulation of iodide in thyroid was found in 1915, radioiodine has been widely applied to diagnose and treat thyroid cancer. Iodide uptake occurs across the membrane of the thyroid follicular cells and cancer cells through an active transporter process mediated by the sodium iodide symporter (NIS). The NIS coding genes were cloned and identified from rat and human in 1996. Evaluation of the NIS gene and protein expression is critical in the management of thyroid cancer, and several approaches have been tried to increase NIS levels. Identification of the NIS gene has provided a means of expanding its role in the radionuclide gene therapy of nonthyroidal cancers as well as thyroid cancer. In this article, we explain the relationship between NIS expression and the treatment of thyroid carcinoma with I-131, and we include a review of the results of our experimental and clinical trials.

Chung JK (2002) Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 43:1188–1200PubMed

Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379:458–460CrossRefPubMed

Ministry of health and welfare (2002) Annual report of the Korea central cancer registry, 2003

Fernandes JK, Day TA, Richardson MS, Sharma AK (2005) Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol 6:47–57CrossRefPubMed

Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F et al (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573CrossRefPubMed

Stojadinovic A, Shoup M, Ghossein RA, Nissan A, Brennan MF, Shah JP et al (2002) The role of operations for distant metastatic well-differentiated thyroid carcinoma. Surgery 131:636–643CrossRefPubMed

Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Frredman S, Brennan MF et al (2003) Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191–197CrossRefPubMed

Hedinger C, Williams ED, Sobin LH et al (1988) Histological typing of thyroid tumours. World Health Organization International Histological Classification of Tumours. Springer Verlag, Berlin

Chung JK, Kang JH (2004) Translational research using the sodium/iodide symporter in imaging and therapy. Eur J Nucl Med Mol Imaging 31:799–802CrossRefPubMed

10.

Chung JK, So Y, Lee JS, Choi CW, Lim SM, Hong SW et al (1999) Value of FDG PET in papillary thyroid carcinoma with negative ¹³¹I whole-body scan. J Nucl Med 40:986–992PubMed

11.

Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD et al (1999) [¹⁸F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic ¹³¹I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–2302CrossRefPubMed

12.

Hooft L, Hoekstra OS, Deville W, Lips P, Tulder GJ, Boers M et al (2001) Diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86:3779–3786CrossRefPubMed

13.

Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ et al (2001) Relationship between expression of the sodium/iodide symporter and I-131 uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 28:639–645CrossRefPubMed

14.

Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742–762CrossRefPubMed

15.

Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P (2006) The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 13:257–269CrossRefPubMed

16.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V et al (2008) BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511–520CrossRefPubMed

17.

Puppin C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G et al (2004) Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1. Endocrinology 145:1290–1293CrossRefPubMed

18.

De Felice M, Di Lauro R (2004) Thyroid development and its disorders: genetics and molecular mechanisms. Endocrine Reviews 25:722–746CrossRefPubMed

19.

Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA (2002) A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3’, 5’-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol 16:2266–2282CrossRefPubMed

20.

Tell G, Pellizzari L, Pucillo C, Puglisi F, Cesselli D, Kelley MR et al (2000) TSH controls Ref-1 nuclear translocation in thyroid cells. J Mol Endocrinol 24:383–390CrossRefPubMed

21.

Tell G, Pellizzari L, Cimarosti D, Pucillo C, Damante G (1998) Ref-1 controls pax-8 DNA-binding activity. Biochem Biophys Res Commun 252:178–183CrossRefPubMed

22.

Ohmori M, Endo T, Harii N, Onaya T (1998) A novel thyroid transcription factor is essential for thyrotropin-induced up-regulation of Na+/I-symporter gene expression. Mol Endocrinol 12:727–736CrossRefPubMed

23.

Chun JT, Di Dato V, D’Andrea B, Zannini M, Di Lauro R (2004) The CRE-like element inside the 50-upstream region of the rat sodium/iodide symporter gene interacts with diverse classes of b-Zip molecules that regulate transcriptional activities through strong synergy with Pax-8. Mol Endocrinol 18:2817–2829CrossRefPubMed

24.

Haugen BR (2004) Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endor Metabol Disord 4:175–180CrossRef

25.

Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 25:131–138CrossRefPubMed

26.

Coelho SM, De Carvalho DP, Vaisman M (2007) New Perspective on the treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 51:612–624PubMed

27.

Kogai T, Taki K, Brent GA (2006) Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 13:797–826CrossRefPubMed

28.

Marcus M, Coulton (2000) Fat-soluble vitamins A, K, E. In: Hadman JG, Limbird LE, Gilman AG (eds) Goodman and Gilmamn’s the pharmacologic basis of therapeutics. Mc Graw Hill, pp 1773–1792

29.

Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J (1997) Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832–838CrossRefPubMed

30.

Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG et al (2005) Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222–231CrossRefPubMed

31.

Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170–2177CrossRefPubMed

32.

Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T et al (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430–3435CrossRefPubMed

33.

Akagi T, Luong QT, Gui D, Said J, Selektar J, Yung A et al (2008) Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 99:781–788CrossRefPubMed

34.

Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K et al (2004) Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865–2875CrossRefPubMed

35.

Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G (2004) Valproic acid induces the expression of the NaC/I-symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89:1006–1009CrossRefPubMed

36.

Venkataraman GM, Yatin M, Ain KB (1998) Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50. Thyroid 8:63–69CrossRefPubMed

37.

Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM (2000) Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167:125–135CrossRefPubMed

38.

Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M et al (2003) The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48–77CrossRefPubMed

39.

De la Vieja A, Ginter CS, Carrasco N (2005) Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I-symporter. Mol Endocrinol 19:2847–2858CrossRefPubMed

40.

Kurebayashi J, Tanaka K, Otsuki T, Moriya T, Kunisue H, Uno M et al (2000) All-trans retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab 85:2889–2896CrossRefPubMed

41.

Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K et al (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569–574CrossRefPubMed

42.

Gruenwald F, Menzel C, Bender H, Palmedo H, Otte R et al (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903–1906

43.

Gruenwald F, Pakos E, Bender H, Menzel C, Otte R, Palmedo H et al (1998) Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 39:1555–1558

44.

Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M et al (2001) Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 42:317–325PubMed

45.

Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T et al (2000) Establishment and characterization of a breast cancer cell line expressing Na+/I-symporters for radioiodide concentrator gene therapy. J Nucl Med 41:1898–1904PubMed

46.

Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S et al (2000) Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 60:3484–3492PubMed

47.

Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al (2001) In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8:1524–1531CrossRefPubMed

48.

Schipper ML, Weber A, Béhé M, Göke R, Joba W, Schmidt H et al (2003) Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 63:1333–1338PubMed

49.

Kang JH, Chung JK, Lee YJ, Shin JH, Jeong JM, Lee DS et al (2004) Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med 45:1571–1576PubMed

50.

Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER et al (2005) Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 12:272–280CrossRefPubMed

51.

Petrich T, Quintanilla-Martinez L, Korkmaz Z, Samson E, Helmeke HJ, Meyer GJ et al (2006) Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors. Clin Cancer Res 12:1342–1348CrossRefPubMed

52.

Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC (2006) Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 17:661–668CrossRefPubMed

53.

Kim HJ, Jeon YH, Kang JH, Lee YJ, Kim KI, Chung HK et al (2007) In vivo long-term imaging and radioiodine therapy by sodium iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter. Cancer Biol Ther 6:1130–1135PubMedCrossRef

54.

Dingli D, Diaz RM, Bergert ER, O'Connor MK, Morris JC, Russell SJ (2003) Genetically targeted radiotherapy for multiple myeloma. Blood 102:489–496CrossRefPubMed

55.

La Perle KM, Blomme EA, Capen CC, Jhiang SM (2003) Effect of exogenous human sodium iodide symporter expression on growth of MATLyLu cells. Thyroid 13:133–140CrossRefPubMed

56.

Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G (2002) Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 13:1723–1735CrossRefPubMed

57.

Lee YJ, Chung JK, Shin JH, Kang JH, Jeong JM, Lee DS et al (2004) In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 14:889–895CrossRefPubMed

58.

Snade JV, Massart C, Beauwens R, Schoutens A, Costagliola S, Dumont JE et al (2003) Anion selectivity by the sodium iodide symporter. Endocrinology 144:247–252CrossRef

59.

Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P et al (2002) Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 12:19–26CrossRefPubMed

60.

Furuya F, Shimura H, Miyazaki A, Taki K, Ohta K, Haraguchi K et al (2004) Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 145:5397–5405CrossRefPubMed

61.

Dadachova E, Carrasco N (2004) The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 34:23–31CrossRefPubMed

62.

McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM et al (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25:1341–1351CrossRefPubMed

63.

Willhauck MJ, Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ et al (2007) Application of rhenium-188 as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 92:4451–4458CrossRefPubMed

64.

Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ et al (2008) The potential of 211astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 35:1272–1281CrossRefPubMed

65.

Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CY, Morris JC (2000) Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60:6526–6530PubMed

66.

Jin YN, Chung HK, Kang JH, Lee YJ, Kimm KI, Kim YJ et al (2008) Radioiodine gene therapy of hepatocellular carcinoma targeted human alpha fetoprotein. Cancer Biother Radiopharm 23:551–560CrossRefPubMed

67.

Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al (2008) Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 15:214–223CrossRefPubMed

68.

Kim SH, Chung HK, Kang JH, Kim KI, Jeon YH, Jin YN et al (2008) Tumor-targeted radionuclide imaging and therapy based on human sodium iodide symporter gene driven by a modified telomerase reverse transcriptase promoter. Hum Gene Ther 19:951–957CrossRefPubMed

Title: Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma
Authors: June-Key Chung
Hye Won Youn
Joo Hyun Kang
Ho Young Lee
Keon Wook Kang
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Nuclear Medicine and Molecular Imaging / Issue 1/2010
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-009-0016-1

At a glance: The STEP trials

Springer Medicine

Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

3′-Deoxy-3′-[18F]fluorothymidine and O-(2-[18F]fluoroethyl)-L-tyrosine PET in Patients with Suspicious Recurrence of Glioma after Multimodal Treatment: Initial Results of a Retrospective Comparative Study

Cerebral Toxoplasmosis in a Patient with AIDS on F-18 FDG PET/CT

Tc-99m Diphosphonate as a Potential Radiotracer to Detect Sentinel Lymph Nodes in Patients with Breast Cancer

Non-Specific Disease Mimicking Malignancy: Two Cases of FDG Uptake in the Extremities

Absent Sternum as the First Manifestation of Bone Metastasis on Bone Scintigraphy

F-18 FDG PET Images of the Cervix at Various Time Points after the Loop Electrosurgical Excision Procedure